GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » EV-to-EBITDA

PCI Biotech Holding ASA (FRA:4QG) EV-to-EBITDA : -0.48 (As of May. 22, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PCI Biotech Holding ASA's enterprise value is €1.33 Mil. PCI Biotech Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-2.78 Mil. Therefore, PCI Biotech Holding ASA's EV-to-EBITDA for today is -0.48.

The historical rank and industry rank for PCI Biotech Holding ASA's EV-to-EBITDA or its related term are showing as below:

FRA:4QG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.9   Med: -7.8   Max: 4.78
Current: -0.52

During the past 13 years, the highest EV-to-EBITDA of PCI Biotech Holding ASA was 4.78. The lowest was -58.90. And the median was -7.80.

FRA:4QG's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.97 vs FRA:4QG: -0.52

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), PCI Biotech Holding ASA's stock price is €0.1178. PCI Biotech Holding ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.072. Therefore, PCI Biotech Holding ASA's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


PCI Biotech Holding ASA EV-to-EBITDA Historical Data

The historical data trend for PCI Biotech Holding ASA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA EV-to-EBITDA Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.78 -12.28 -4.73 -0.44 -1.57

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.44 -0.69 -1.13 -

Competitive Comparison of PCI Biotech Holding ASA's EV-to-EBITDA

For the Biotechnology subindustry, PCI Biotech Holding ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's EV-to-EBITDA falls into.



PCI Biotech Holding ASA EV-to-EBITDA Calculation

PCI Biotech Holding ASA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1.334/-2.776
=-0.48

PCI Biotech Holding ASA's current Enterprise Value is €1.33 Mil.
PCI Biotech Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (FRA:4QG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PCI Biotech Holding ASA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1178/-0.072
=At Loss

PCI Biotech Holding ASA's share price for today is €0.1178.
PCI Biotech Holding ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.072.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


PCI Biotech Holding ASA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (FRA:4QG) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (FRA:4QG) Headlines

No Headlines